Previous Close | 0.2694 |
Open | 0.2788 |
Bid | 0.0000 x 900 |
Ask | 0.2800 x 800 |
Day's Range | 0.2600 - 0.2788 |
52 Week Range | 0.1750 - 15.2000 |
Volume | |
Avg. Volume | 898,015 |
Market Cap | 10.966M |
Beta (5Y Monthly) | 1.01 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for AGRX
FDA Agrees to Extended Milestones for Long-Term Twirla® Safety Study New Publication Supports Eventual Pursuit of AG200-15 Extended Regimen Development Program PRINCETON, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today provided an update on the Twirla® post-marketing studies and status of its ongoing evaluation of the Company’s pipeline. Twirla Post-Marketing Studies As part of Twirla’s approval, the United States Food and Drug
PRINCETON, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on February 6, 2023. The shares of Series C Preferred Stock will be distributed to such recipients at 5:0
By Johnny Rice, Benzinga